MHRA Inspection
May 23, 2023
Successful MHRA inspection
Pharmidex are pleased to announce we have for another year had a successful GLP compliance inspection by MHRA. The inspection took place at our facilities in Hatfield on 8th-9th November 2022.
ο»Ώ
MHRA reported that they did not find any critical or major issues during the inspection and announced that Pharmidex can continue to be a compliant member of MHRA GLP.
We are pleased to announce that Martin Barrett , our Head of Business Development, will be attending the Making & Distributing Pharmaceuticals UK event on 29–30 April 2025 at the Coventry Building Society Arena! π ( https://lnkd.in/gd73pvE ) Martin would be delighted to meet with fellow attendees to discuss new collaboration opportunities and how we can work together to advance the development of innovative drug candidates. If you are attending, don’t miss the chance to connect with us and explore how we can drive pharmaceutical progress forward together!
We’re excited that Ash Alavijeh , our Head of Operations, will attend the Biotech Matchmaking Event on 29 April 2025 at the Old Divinity School, St John’s College, Cambridge. π (Biotech Matchmaking Event - The Milner Therapeutics Institute) Ash looks forward to meeting attendees, discussing new collaborations, and driving forward the development of innovative drug candidates. ο»Ώ If you're attending, let’s connect and explore new opportunities together!
We at Pharmidex have been delighted to collaborate closely with the talented teams at Apeikon Therapeutics and King's College London to generate exciting new data in the field of oncology research. We are proud to share that our collaborative poster will be presented this afternoon at the AACR Annual Meeting 2025 in Chicago! πΊπΈβ¨ π Check out the poster and learn more here: https://lnkd.in/e7-TVBB9 A huge thank you to everyone involved for making this project a success, we are looking forward to continuing to push the boundaries of discovery together! If you're attending AACR, come and visit, we would love to discuss our findings and explore new opportunities for collaboration.
